University of Cambridge > Talks.cam > Isaac Newton Institute Seminar Series > Imaging biomarkers in Alzheimer's Disease: the technical and regulatory challenges of global deployment

Imaging biomarkers in Alzheimer's Disease: the technical and regulatory challenges of global deployment

Add to your list(s) Download to your calendar using vCal

If you have a question about this talk, please contact Mustapha Amrani.

Inverse Problems

Drug development involves huge and extremely expensive global experiments, which at late phase can involve many thousands of patients recruited at 100s of hospitals all over the world. Imaging biomarkers have the potential to provide standardized, quantitative measurements of patient eligibility for the study, drug side effects, and drug efficacy, but deploying them in such global studies has great challenges. Alzheimer’s Disease (AD) is an area of huge unmet medical need, and huge sums are being invested in testing potential new treatments for AD, and drug companies are being very ambitious in their use of sophisticated image analysis methods in these studies. The technical and regulatory challenges of these applications is quite different from the normal focus of image analysis research, but the potential benefit of overcoming these challenges is better tools to help bring safe and effective medicines to patients.

This talk is part of the Isaac Newton Institute Seminar Series series.

Tell a friend about this talk:

This talk is included in these lists:

Note that ex-directory lists are not shown.

 

© 2006-2021 Talks.cam, University of Cambridge. Contact Us | Help and Documentation | Privacy and Publicity